Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute effects of methylphenidate, atomoxetine, and citalopram on cognitive control brain activity in healthy volunteers
ACTRN12609000625279Phase 4Completed
- Sponsor
- Queensland Brain Institute
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of methylphenidate, atomoxetine and citalopram in attention deficit hyperactivity disorder (ADHD) and major depressive disorder (MDD), sponsored by Queensland Brain Institute. Primary endpoints: Cognitive task performance and EEG neural activity and Cognitive task performance and fMRI neural activation. Started Jul 2009; status: completed.
02
Drugs
methylphenidateatomoxetinecitalopram
03
Conditions
attention deficit hyperactivity disorder (ADHD)major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12609000625279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000625279.